Amphastar Poised To Receive $59.9m In Momenta/Sandoz Settlement
The small generic drug company has talked about using the cash windfall from the expected settlement to fund clinical trials and possibly M&A.
You may also be interested in...
Momenta Pharmaceuticals has agreed to pay $35.0m to settle claims that it manipulated generic approval processes in the US to shut competitor Amphastar out of the US enoxaparin market.
Long-running US patent and antitrust litigation between Sandoz, Momenta and Amphastar over enoxaparin has been brought to an end after the parties agreed a settlement deal.
Momenta and Sandoz face the prospect of paying treble damages to Amphastar over allegations the two firms “restricted trade and prevented competition in the manufacture and sale of generic enoxaparin” in the US, after a district judge denied Momenta’s bid to dismiss the US-based specialty company’s antitrust lawsuit.